News

Enlarge image

BusinessItalyFranceBulgaria

Sanofi ramps up artemisinin plant

12.04.2013 - From its Italian manufacturing site at Garessio, Sanofi has launched large-scale production of semi-synthetic artemisinin, a potent anti-malarial drug.

The launch of the new facility on April 11 represents a further milestone in an anti-malarial drug partnership led by OneWorld Health, a non-profit drug development organisation, with funding from the Bill & Melinda Gates Foundation. Sanofi has invested €10m to build an industrial-scale plant that converts the biological precursor artemisinic acid into artemisinin in reaction steps that involve photochemistry. With its photochemical batch-flow-reactor technology in action, Sanofi envisions a production of 35 tonnes of semi-synthetic artemisinin in 2013, with the first batches available by this summer. It plans to increase capacity to 60 tonnes per year in 2014 and thereafter, which would meet at least a third of the annual global need for the drug. Sanofi hopes to get WHO approval for its product in the coming weeks.

From a technology perspective, the semi-synthetic artemisinin project is a combination of biotechnological and chemical know-how at the industrial scale. Artemisinin is a secondary metabolite extracted from the traditional Chinese medical herb Artemisia annua. However, the botanical supply is subject to climatic variables, leading to a fluctuation in antimalarial medicines and big price variations. Aiming for a stable and more reliable supply of the drug, Jay Keasling and his team at the University of California Berkeley and synthetic biology start-up Amyris genetically engineered yeast cells to produce the precursor artemisinic acid, which must then be converted into artemisinin by synthetic organic chemistry. Sanofi entered the project in 2008 as manufacturing partner with its Access to Medicines programme, and was involved in scaling-up fermentation of artemisinic acid and its conversion into artemisinin using photochemistry. At a facility run by Huverpharma in Bulgaria, an industrial-scale fermentation process was established that could produce up to 100 tonnes of artemisinic acid annually. It is considered as the first industrial-scale deployment of synthetic biology for drug production. Sanofi said it will provide its semi-synthetic artemisinin at a stable price using a non-profit, non-loss production model.

© eurobiotechnews.eu/pg

http://www.european-biotechnology-news.com/news/news/2013-02/sanofi-ramps-up-artemisinin-plant.html

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Immuno-oncologyNetherlandsBelgium

21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

RegulatorySwitzerlandEU

20.04.2016 The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available.

Immuno-oncologyUK

19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.

FinancingSwitzerlandFranceEUGermanyDenmark

15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.

Event ReviewSwitzerlandBelgiumEU

13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

München

BioVaria 2016

Berlin (GER)

XIV. BIONNALE 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • KAROLINSKA (S)7.85 SEK9.03%

FLOP

  • IMMUPHARMA (UK)26.50 GBP-10.17%
  • DBV TECHNOLOGIES (F)53.40 EUR-5.79%
  • FLAMEL TECHNOLOGIES (F)11.37 USD-4.29%

TOP

  • BIOFRONTERA (D)3.26 EUR39.3%
  • SYNAIRGEN (UK)35.50 GBP36.5%
  • SWEDISH ORPHAN BIOVITRUM (S)15.24 USD27.5%

FLOP

  • EVOCUTIS (UK)0.05 GBP-28.6%
  • THERAMETRICS (CH)0.03 CHF-25.0%
  • OREXO (S)47.10 SEK-22.1%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)28.40 SEK1818.9%
  • NICOX (F)8.01 EUR321.6%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.30 SEK-87.7%
  • BB BIOTECH (D)44.01 EUR-83.2%
  • CYTOS (CH)0.25 CHF-78.6%

No liability assumed, Date: 05.05.2016